Hansa Biopharma AB (publ)
HNSBF News Today: Stay Updated with the Latest Hansa Biopharma AB (publ) News in Real Time
Find HNSBF news now at Meyka AI. Stay informed with the latest Hansa Biopharma AB (publ) stocks updates, including price news, market analysis, and expert insights.
10 Apr 2026: B8F.DE Biofrontera AG XETRA pre-market rises to €6.80 on heavy volume
Pre-market update on B8F.DE stock: price €6.80 on heavy volume; Meyka AI grade and €9.00 forecast
09 Apr 2026 PRFN.SW Kinarus (SIX) -8.12% on 2.94M vol: PRFN.SW stock at CHF0.0362 support
PRFN.SW stock fell to CHF0.0362 on 09 Apr 2026 with 2.94M shares traded; intraday drivers, Meyka AI grade and forecast included
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 PT $16
Jefferies kept Buy and raised PT to $16 for CytomX; CTMX analyst rating and investor implications
XVIPY Xvivo Perfusion PNK $6.54 08 Apr 2026: Oversold bounce may reach $9.58
XVIPY stock update: $6.54, oversold-bounce setup with Meyka AI forecast to $9.58 and 46.48% upside
Evotec SE (EVT.DE XETRA) 06 Apr 2026 earnings preview: valuation test ahead
EVT.DE stock trades at EUR 4.50 ahead of 08 Apr 2026 earnings; we review guidance risks, Meyka forecast and price targets for traders
^GSPC Today April 03: Pharma 100% Tariff, Metals Duty Overhaul
Trump tariffs shake markets as pharma faces a 100% headline rate and metals duties tighten to spot prices. What this means for HK investors and the S&P 500 today.
CSCI.TO COSCIENS Biopharma (TSX) up 90.08% intraday 02 Apr 2026: catalyst, outlook
Intraday: CSCI.TO stock jumps 90.08% to C$2.30 on 02 Apr 2026; volume surge and Meyka forecast analysis
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+
Barclays Maintains Overweight on Incyte (INCY) Mar 2026
INCY analyst rating: Barclays maintained Overweight on Incyte in Mar 2026, implications for investors and price context